Oncogene:FDPS能与PTEN功能丧失协作促进前列腺癌恶化

2019-04-10 AlexYang MedSci原创

法尼基焦磷酸合酶(FDPS)是一种甲羟戊酸途径酶,在一些癌症中高度表达,其中也包括了前列腺癌(PCa)。到目前为止,癌症中FDPS的机制、功能和临床意义仍旧还未探索。最近,有研究人员在PTEN功能缺陷和正常的人类和小鼠PCa细胞和肿瘤中评估了FDPS的表达以及其与癌症相关的表型。研究发现,FDPS的过表达与PTEN缺失在PTEN条件性敲除小鼠(P<0.05)中表现出协同作用(P<0.0

法尼基焦磷酸合酶(FDPS)是一种甲羟戊酸途径酶,在一些癌症中高度表达,其中也包括了前列腺癌(PCa)。到目前为止,癌症中FDPS的机制、功能和临床意义仍旧还未探索。

最近,有研究人员在PTEN功能缺陷和正常的人类和小鼠PCa细胞和肿瘤中评估了FDPS的表达以及其与癌症相关的表型。研究发现,FDPS的过表达与PTEN缺失在PTEN条件性敲除小鼠(P<0.05)中表现出协同作用(P<0.05),并且在人类(P<0.01)PCa组织、细胞系和小鼠类瘤中分别比相应对照表达显著更高。生物信息学分析阐释了FDPS与格林森评分的增加、PTEN功能性缺失状态和PCa不良预后相关。FDPS的异位过表达能够通过激活AKT和ERK信号途径来促进肿瘤表型的产生,比如群落形成(p<0.01)和增殖(p<0.01)。有趣的是,PCa细胞中FDPS的敲除表现出了群落生长和增殖的减少(p<0.001),具体也是通过调控AKT和ERK途径。更多的是,PI3K的遗传和药理学抑制能够减少FDPS的表达,而AKT没有上述效果。 通过唑来膦酸(ZOL)对FDPS进行药理学靶定表现出了人类和小鼠PCa细胞(p<0.01)和3D类瘤(p<0.02)集群和生长的减少,具体是通过直接干扰小GTP酶蛋白的异戊烯化来干扰AKT和ERK信号途径来实现的。

最后,研究人员指出,FDPS通过GTP酶/AKT途径在PTEN缺失的PCa中具有致瘤的作用。鉴定甲羟戊酸途径蛋白质能够在PTEN异常的肿瘤中作为治疗靶标。

原始出处:

Parthasarathy Seshacharyulu, Satyanarayana Rachagani, Sakthivel Muniyan et al. FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis. Oncogene. 26 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049170, encodeId=a63420491e0a8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Jun 25 03:41:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315934, encodeId=988c13159345e, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558150, encodeId=4b6315581502d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364434, encodeId=26663644343a, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Apr 10 18:39:24 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040434, encodeId=b249104043413, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 17:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-06-25 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049170, encodeId=a63420491e0a8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Jun 25 03:41:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315934, encodeId=988c13159345e, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558150, encodeId=4b6315581502d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364434, encodeId=26663644343a, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Apr 10 18:39:24 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040434, encodeId=b249104043413, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 17:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-12 xiaogang317
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049170, encodeId=a63420491e0a8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Jun 25 03:41:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315934, encodeId=988c13159345e, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558150, encodeId=4b6315581502d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364434, encodeId=26663644343a, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Apr 10 18:39:24 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040434, encodeId=b249104043413, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 17:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-12 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049170, encodeId=a63420491e0a8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Jun 25 03:41:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315934, encodeId=988c13159345e, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558150, encodeId=4b6315581502d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364434, encodeId=26663644343a, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Apr 10 18:39:24 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040434, encodeId=b249104043413, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 17:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 orangesking

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2049170, encodeId=a63420491e0a8, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Jun 25 03:41:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315934, encodeId=988c13159345e, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558150, encodeId=4b6315581502d, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Apr 12 05:41:00 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364434, encodeId=26663644343a, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Apr 10 18:39:24 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040434, encodeId=b249104043413, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Apr 10 17:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=)]
    2019-04-10 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

EBioMedicine:细胞分裂周期蛋白20(CDC20)能够促使前列腺癌的恶化

细胞分裂周期蛋白20(CDC20)在恶性肿瘤中经常过表达并且还参与了造血干细胞的分化过程。然而,CDC20在前列腺癌类干细胞(CSCs)中中的作用仍旧所知较少。最近,有研究人员通过免疫组化染色对前列腺癌样本中的CDC20、CD44和β-连环蛋白表达进行了分析,并通过实时定量PCR、球体形成、体内外有限稀释试验对CDC20对类干细胞特性的前列腺CSCs作用进行了评估。研究发现,CDC20与前列腺癌的

Oncogenesis:CUL4B能够通过与SOX4形成正反馈循环促进前列腺癌恶化

怎样从恶性疾病中区分无痛性疾病在前列腺癌(PCa)的治疗中仍旧是一个巨大的挑战。Cullin 4B (CUL4B)是一种支架蛋白并且在多种人类恶性肿瘤中表现出了致瘤活性。最近,有研究人员利用PCa组织样本、细胞系和异种种植模型确定了是否CUL4B能够导致PCa恶化和转移。研究发现,CUL4B的表达与PCa的恶化过程相关。CUL4B的表达能够促进PCa细胞的增殖、上皮间质转化和PCa细胞的转移,而C

EBioMedicine:前列腺癌治疗药物新发现

基因组规模的代谢模型(GEMs)为癌症代谢提供了新的认识,并且已经用于鉴定潜在的生物标记和药物靶标。药物重定位是一种既省时又省力的药物发现的方法,并且可以与GEMs一起用于癌症的有效治疗。最近,有研究人员构建了一个前列腺癌(PRAD)特异性GEM,用来探索前列腺癌代谢,并且探索新的可以用于有效癌症治疗的药物。研究人员通过使用前列腺癌GEM模型对多于1000中不同的药物进行了整体的基因表达分析,并预

Prostate Cancer P D: 前列腺癌SLCO基因表达与格林森等级和雄激素阻断治疗后变化相关性分析

雄激素阻断治疗(ADT)后,SLCO编码的转运蛋白与去势难治性前列腺癌(CRPC)的恶化相关。尽管比CRPC组织中的表达水平更低,SLCO编码的转运蛋白可能在原发性前列腺癌(PCa)对ADT和生化复发响应中具有作用。最近,有研究人员系统性的探索了11个人类SLCO基因的表达在正常的前列腺(NP)和ADT治疗和未治疗的原发性PCa组织中的表达情况,包括了阿比特龙新辅助治疗的肿瘤。研究发现,在PCa中

Prostate:未经激素治疗前列腺癌中tSTAT3、pSTAT3 727和pSTAT3 705的表达研究

信号转导和激活转录因子3(STAT3)途径在一些恶性肿瘤中持续性的激活,其中包括了前列腺癌(PCa)。最近,有研究人员在2个未经激素治疗的局部PCa患者群体的组织芯片中,调查了总STAT3(tSTAT3)和2种激活形式的磷酸化STAT3(pSTAT3 727和pSTAT3 705)的表达情况,并且分析了表达与疾病结果的相关性情况。研究发现,tSTAT3、pSTAT3 727和pSTAT3 705在

Eur Urol:重点治疗后机器人辅助的根治性前列腺切除术的效果研究

那些经历重点治疗(FT)后的前列腺癌(PC)局部复发患者,进行根治性前列腺切除术(RP)后的结果和毒性情况的相关研究很少。最近,有研究人员对进行抢救性机器人协助RP(S-RALP)的患者的围手术期,肿瘤和功能结果情况进行了鉴定,并确定了S-RALP失败的风险因素。研究是一个多中心的群体研究,包括了82名在FT后经历S-RALP的患者。所有的参与者均具有组织学确定的PC复发。研究发现,无进展生存在术